J
Julie A. Johnson
Researcher at University of Florida
Publications - 422
Citations - 27067
Julie A. Johnson is an academic researcher from University of Florida. The author has contributed to research in topics: Pharmacogenetics & Pharmacogenomics. The author has an hindex of 76, co-authored 399 publications receiving 24016 citations. Previous affiliations of Julie A. Johnson include National Institutes of Health & University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
Estimation of the warfarin dose with clinical and pharmacogenetic data
Teri E. Klein,Russ B. Altman,Niclas Eriksson,Brian F. Gage,Stephen E. Kimmel,Lee Mt,Nita A. Limdi,David C. Page,Dan M. Roden,Michael J. Wagner,Caldwell,Julie A. Johnson +11 more
TL;DR: The use of a pharmacogenetic algorithm for estimating the appropriate initial dose of warfarin produces recommendations that are significantly closer to the required stable therapeutic dose than those derived from a clinical algorithm or a fixed-dose approach.
Journal ArticleDOI
Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells
Jonathan S. Draper,Kath Smith,Paul J. Gokhale,Harry Moore,Edna Maltby,Julie A. Johnson,Lorraine F. Meisner,Thomas P. Zwaka,James A. Thomson,Peter W. Andrews +9 more
TL;DR: It is suggested that increased dosage of chromosome 17q and 12 gene(s) provides a selective advantage for the propagation of undifferentiated hES cells in transplantation therapies in which the use of aneuploid cells could be detrimental.
Journal ArticleDOI
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Stuart A. Scott,Katrin Sangkuhl,Charles M. Stein,Jean-Sébastien Hulot,Jean-Sébastien Hulot,Jessica L. Mega,Dan M. Roden,Teri E. Klein,Marc S. Sabatine,Julie A. Johnson,Julie A. Johnson,Alan R. Shuldiner,Alan R. Shuldiner +12 more
TL;DR: In this article, an expanded literature review showed that CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel-treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI).
Journal ArticleDOI
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
Brian F. Gage,Charles S. Eby,Julie A. Johnson,Elena Deych,Mark J. Rieder,Paul M. Ridker,Paul E. Milligan,Gloria R. Grice,Petra A. Lenzini,Allan E. Rettie,Christina L. Aquilante,Christina L. Aquilante,Leonard E. Grosso,Sharon Marsh,Taimour Y. Langaee,LE Farnett,Deepak Voora,Deepak Voora,David L. Veenstra,Robert J. Glynn,A Barrett,Howard L. McLeod,Howard L. McLeod +22 more
TL;DR: The goal was to develop and validate a pharmacogenetic algorithm that explained 53–54% of the variability in the warfarin dose in the derivation and validation cohorts.
Journal ArticleDOI
A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing
Stephen E. Kimmel,Benjamin French,Scott E. Kasner,Julie A. Johnson,Jeffrey L. Anderson,Brian F. Gage,Yves Rosenberg,Charles S. Eby,Rosemary Madigan,Robert B. McBane,Sherif Z. Abdel-Rahman,Scott M. Stevens,Steven H. Yale,Emile R. Mohler,Margaret C. Fang,Vinay Shah,Richard B. Horenstein,Nita A. Limdi,James A.S. Muldowney,Jaspal S Gujral,Patrice Delafontaine,Robert J. Desnick,Thomas L. Ortel,Henny H. Billett,Robert C. Pendleton,Nancy L. Geller,Jonathan L. Halperin,Samuel Z. Goldhaber,Michael D. Caldwell,Robert M. Califf,Jonas H. Ellenberg +30 more
TL;DR: Genotype-guided dosing of warfarin did not improve anticoagulation control during the first 4 weeks of therapy and there was a significant interaction between dosing strategy and race.